Clinical Study of 18F Labeled Probe Targeting Fibroblast Activating Protein and Integrin avβ3 (FAPI-RGD) in Interstitial Lung Disease Associated With Connective Tissue Disease
Overview
- Phase
- Not Applicable
- Intervention
- Not specified
- Conditions
- Interstitial Lung Disease
- Sponsor
- Sichuan Provincial People's Hospital
- Enrollment
- 30
- Locations
- 1
- Primary Endpoint
- Correlation between clinical indicators and PET/CT results
- Status
- Recruiting
- Last Updated
- 2 years ago
Overview
Brief Summary
The goal of this observational study is to examine clinical utility of 18F-FAPI-RGD PET/CT imaging in evaluating connective tissue disease-associated interstitial lung disease. Participants will undergo clinical evaluation and 18F-FAPI-RGD PET/CT examination.
Detailed Description
Interstitial lung disease is an overarching term for a wide range of disorders characterized by inflammation and/ or fibrosis in the lungs. Interstitial lung disease associated connective tissue diseases(CTD-ILD) is one of the most common types.The goal of this study is to explore the feasibility of using 18F-FAPI-RGD, a dual-targeting heterodimeric PET tracer that recognizes both fibroblast activation protein (FAP) and integrin αvβ3 for detecting connective tissue disease associated interstitial lung disease (CTD-ILD), and analyze the relationship between 18F- FAPI-RGD PET/CT images and related parameters of lung function, clinical laboratory indicators and HRCT scores.
Investigators
Hao Wang
Associate senior physician
Sichuan Provincial People's Hospital
Eligibility Criteria
Inclusion Criteria
- •Age 18 and above
- •Patients who have been diagnosed with, or are clinically highly suspected of ILD
- •Patients who have been diagnosed with, or are clinically highly suspected of CTD-ILD
Exclusion Criteria
- •Pregnant or breastfeeding
- •Patients with tumor, other respiratory diseases, and lung surgery
- •Abnormal cardiopulmonary function or mental state, unable tolerate PET/CT
Outcomes
Primary Outcomes
Correlation between clinical indicators and PET/CT results
Time Frame: 2 months
Correlation of clinical pulmonary function indexes, HRCT, laboratory examination indexes and 18F-FAPI-RGD PET/CT results